ストックスクリーナーアプリを入手
160.06
4.02%
6.19
プレマーケット:
160.72
0.66
+0.41%
Revolution Medicines Inc (RVMD) 最新ニュース
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS - GlobeNewswire Inc.
Revolution Medicines (NASDAQ: RVMD) insider sells 132,871 shares totaling $19.29M - Stock Titan
Revolution Medicines (NASDAQ: RVMD) affiliate reports sale of 2,958 shares under Rule 144 - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider sale of 2,753 shares for $273,869.54 - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider sales total 43,691 shares reported - Stock Titan
Stephen M. Kelsey (RVMD) files to sell 4,071 restricted shares; prior 4,302 sold - Stock Titan
Insider sale: Margaret Horn notifies sale of 14,583 RVMD shares (RVMD) - Stock Titan
RVMD: 90,000 shares registered for sale after option exercise (RVMD) - Stock Titan
[Form 4] Revolution Medicines, Inc. Insider Trading Activity - Stock Titan
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy - Yahoo Finance
Revolution Medicines upgraded to buy after Dara... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Revolution Medicines: Strong Data, Big Market (Rating Upgrade) - Seeking Alpha
Revolution Medicines (RVMD) Stock After RASolute 302 Phase 3 Success A Fresh Look At Valuation - simplywall.st
Number of shareholders of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Bernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendation - MSN
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD - Yahoo Finance
RVMD: Insider files Form 144 to sell 10,000 shares (NASDAQ: RVMD) - Stock Titan
Can Revolution Medicines Be a Game-Changer Stock? - The Motley Fool
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $220 - GuruFocus
Revolution Medicines Inc. Warrant (RVMDW) Edges Higher Amid Modest Trading ActivityFibonacci Entry Signals - newsline.com
Tango shares surge on early pancreatic cancer combination data - The Pharma Letter
UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $175 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Tango Dances Toward Phase III With Positive Vopimetostat/Daraxonrasib Data - Citeline News & Insights
Revolution Medicines (RVMD) Reports Promising Data on Vopimetost - GuruFocus
Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment - Barron's
Biotech Surges 45% On Eye-Popping Pancreatic Cancer Test - Investor's Business Daily
Revolution Medicines (RVMD) Strengthens PDAC Position with New D - GuruFocus
‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response - BioSpace
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller? - Insider Monkey
Why Revolution Medicines (RVMD) Is Down 8.8% After Phase 3 Daraxonrasib Pancreatic Cancer Survival Data Release And What's Next - simplywall.st
J&J spends $1 billion to enter KRAS race for cancer treatments - statnews.com
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate - statnews.com
Revolution Medicines, Inc. (RVMD) Stock Analysis: Unlocking a 24.86% Upside Amidst Biotech Breakthroughs - DirectorsTalk Interviews
Total equity of Revolution Medicines, Inc. – XETR:42Z - TradingView
Debt to assets ratio of Revolution Medicines, Inc. – XETR:42Z - TradingView
ETFs Investing in Revolution Medicines, Inc. Stocks - TradingView
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Earnings call transcript: Revolution Medicines Q1 2026 focuses on strong cash position - Investing.com
Revolution Medicines (RVMD) Drops 4% as Biotech Sector Faces Renewed PressureTrading Ideas - newsline.com
Revolution Medicines in the spotlight for earnings post-trial win By Investing.com - Investing.com Nigeria
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report? - Yahoo Finance
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec - Endpoints News
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
Revolution Medicines is up 97% this year: Here are the bull and bear cases for this soaring biotech stock - MSN
Revolution Medicines Stock Surges on Promising Cancer Drug Data - IndexBox
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. - The Motley Fool
Redwood City company develops pill to treat pancreatic cancer, and trial results are promising - NBC Bay Area
What RevMed’s pancreatic cancer drug meant for one patient - statnews.com
Assessing Revolution Medicines (RVMD) Valuation After Positive Daraxonrasib Phase 3 Results At ASCO 2026 - Yahoo Finance
1.75%
1.09%
大文字化:
|
ボリューム (24 時間):